In the randomized phase III ALPINE study, zanubrutinib was compared head-to-head with ibrutinib as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Brown et al presented results from a progression-free survival analysis of the trial at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract LBA-6).
